Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

Overview of attention for article published in Clinical Cancer Research, March 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 1 X user
patent: 45 patents

wikipedia: 1 Wikipedia page

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 45 patents that reference this research output.

METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS

Application EP-4803535-A2

European Patent Office

09 Sep 2026

Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

Grant US-12606636-B2

United States of America

21 Apr 2026

Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid…

Grant US-12594321-B2

United States of America

07 Apr 2026

MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR…

Application EP-4643874-A2

European Patent Office

05 Nov 2025

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 41 additional patents.